References
- Kulin N A, Pastuszak A, Sage S R, Schick‐Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein‐Schechman A K, Cook L, Brochu J, Rieder M, Koren G. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609–610, [PUBMED], [INFOTRIEVE]
- Chambers C, Johnson K, Dick L, Felix R, Jones K L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010–1015, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Goldstein D J. Effects of third trimester fluoxetine exposure on the newborn. Clin Psychopharmacol 1995; 15: 417–420, [CROSSREF]
- Nordeng H, Lindemann R, Perinov K V, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001; 90: 288–291, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Stiskal J A, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syndrome. Arch Dis Child, Fetal Neonatal Ed 2001; 84: 134–135, [CROSSREF]
- Dahl M, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatr 1997; 171: 392
- Fitzgerald M. Pain in infancy: some unanswered questions. Pain Rev 1995; 2: 77–91
- Fitzgerald M. Neonatal pharmacology of pain. The Pharmacology of Pain, A H Dickenson, J‐M R Besson, I Appleton. Springer, New York 1997
- De Ceballos M L, Benedi A, Urdin C, Del Rio J. Prenatal exposure of rats to antidepressant drugs down‐regulates beta‐adrenoreceptors and 5‐HT2 receptors in cerebral cortex: lack of correlation between 5‐HT2 receptors and serotonin‐mediated behaviour. Neuropharmacology 1985; 24: 947–952, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Cohen L S, Heller V L, Bailey J W, Grush L, Abolon J S, Bouffard S M. Birth outcomes foolowing prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48: 996–1000, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Oberlander T F, Eckstein Grunau R, Fitzgerald C, Ellwood A L, Misri S, Rurak D, Riggs K W. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002; 51: 443–453, [PUBMED], [INFOTRIEVE]
- Price J S, Waller P C, Wood S M, Mackay A VP. A comparison of the post‐marketing safety of four selective serotonin re‐uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42: 757–763, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nordeng H, Lindemann R, Perminov K V, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001; 90: 288–291, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Costei A M, Kozer E, Ho T, Ito S, Koren S. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156: 1129–1132, [PUBMED], [INFOTRIEVE]
- Isbiter G K, Dawson A, Whyte I M. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome. Arch Dis Child, Fetal Neonatal Ed 2001; 85: F147–F148